News and reflections from the world of AI

Use of AI for identification and research of orthohantavirus infections

Introduction Orthohantaviruses are globally spread zoonotic pathogens typically causing chronic asymptomatic infection in rodents. However, humans can be infected through contact with rodent urine, saliva, or feces, causing severe health consequences, such as hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). The mechanisms of the virus, though, are unclear.

Aiforia appoints VP of Sales, Americas

Aiforia, a software company providing pathologists with AI-based solutions for clinical diagnostics and preclinical analysis, today announced that Marco Comianos has joined the company as VP of Sales, Americas. Comianos will oversee sales efforts, as well as driving new business, revenue growth, and more partnerships with top hospitals and pharma companies across the region.

Aiforia launches a collaboration with Mayo Clinic to transform pathology practice with AI-powered solutions

Aiforia, a technology company providing deep learning AI software for image analysis in pathology, and Mayo Clinic announced today that they are collaborating to establish an AI-powered pathology research support architecture at the Mayo Clinic. Leveraging each other’s expertise in digital pathology and deep learning, the two aim to enable faster results and scalable studies in translational ...

End of year message from the CEO

Hi everyone,

Using AI-based image analysis to predict ovarian tumor outcome

High-grade extrauterine serous carcinoma (HGSC) is an aggressive tumor with high rates of recurrence, mainly found in ovaries. These tumors have significant genetic and morphologic heterogeneity and are notable for their diversity and unpredictability in outcome. Treatment methods and research for these tumors have developed very little in the last few decades. Standard therapy includes debulking ...

Aiforia achieves CE-IVD mark for clinical PD-L1 AI model in lung cancer diagnostics

Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 million deaths occurring¹. Fortunately immunotherapies are increasing in prominence and efficacy². A popular target for these novel therapeutics is PD-L1, a vital biomarker indicating cancer progression³. The calculation of PD-L1 presence in tumors is routinely used in clinical pathology as a ...